The effectiveness of adalimumab treatment for non-infectious uveitis

Research output: Contribution to journalReview article

Abstract

Uveitis, which is a major cause of blindness worldwide, is defined as intraocular inflammation that affects the iris, ciliary body, vitreous, retina and choroid. Tumor necrosis factor-alpha (TNF-α) is a key cytokine involved in the pathogenesis of many inflammatory diseases including uveitis. Corticosteroids and immunosuppressive agents are the conventional therapy to treat non-infectious uveitis. In cases that are resistant to these therapies, anti-TNF agents are added. An anti-TNF-α agent, adalimumab, was recently approved for the treatment of refractory non-infectious uveitis. In this review, we provide an introduction to uveitis and summarize the effectiveness and safety of adalimumab in the treatment of non-infectious uveitis.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalImmunological Medicine
Volume42
Issue number2
DOIs
Publication statusPublished - Apr 3 2019

Fingerprint

Uveitis
Tumor Necrosis Factor-alpha
Ciliary Body
Choroid
Iris
Blindness
Immunosuppressive Agents
Retina
Adalimumab
Adrenal Cortex Hormones
Cytokines
Inflammation
Safety
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

The effectiveness of adalimumab treatment for non-infectious uveitis. / Hasegawa, Eiichi; Takeda, Atsunobu; Yawata, Nobuyo; Sonoda, Koh Hei.

In: Immunological Medicine, Vol. 42, No. 2, 03.04.2019, p. 79-83.

Research output: Contribution to journalReview article

@article{c63fae924e984925842b9d9bb471561b,
title = "The effectiveness of adalimumab treatment for non-infectious uveitis",
abstract = "Uveitis, which is a major cause of blindness worldwide, is defined as intraocular inflammation that affects the iris, ciliary body, vitreous, retina and choroid. Tumor necrosis factor-alpha (TNF-α) is a key cytokine involved in the pathogenesis of many inflammatory diseases including uveitis. Corticosteroids and immunosuppressive agents are the conventional therapy to treat non-infectious uveitis. In cases that are resistant to these therapies, anti-TNF agents are added. An anti-TNF-α agent, adalimumab, was recently approved for the treatment of refractory non-infectious uveitis. In this review, we provide an introduction to uveitis and summarize the effectiveness and safety of adalimumab in the treatment of non-infectious uveitis.",
author = "Eiichi Hasegawa and Atsunobu Takeda and Nobuyo Yawata and Sonoda, {Koh Hei}",
year = "2019",
month = "4",
day = "3",
doi = "10.1080/25785826.2019.1642080",
language = "English",
volume = "42",
pages = "79--83",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - The effectiveness of adalimumab treatment for non-infectious uveitis

AU - Hasegawa, Eiichi

AU - Takeda, Atsunobu

AU - Yawata, Nobuyo

AU - Sonoda, Koh Hei

PY - 2019/4/3

Y1 - 2019/4/3

N2 - Uveitis, which is a major cause of blindness worldwide, is defined as intraocular inflammation that affects the iris, ciliary body, vitreous, retina and choroid. Tumor necrosis factor-alpha (TNF-α) is a key cytokine involved in the pathogenesis of many inflammatory diseases including uveitis. Corticosteroids and immunosuppressive agents are the conventional therapy to treat non-infectious uveitis. In cases that are resistant to these therapies, anti-TNF agents are added. An anti-TNF-α agent, adalimumab, was recently approved for the treatment of refractory non-infectious uveitis. In this review, we provide an introduction to uveitis and summarize the effectiveness and safety of adalimumab in the treatment of non-infectious uveitis.

AB - Uveitis, which is a major cause of blindness worldwide, is defined as intraocular inflammation that affects the iris, ciliary body, vitreous, retina and choroid. Tumor necrosis factor-alpha (TNF-α) is a key cytokine involved in the pathogenesis of many inflammatory diseases including uveitis. Corticosteroids and immunosuppressive agents are the conventional therapy to treat non-infectious uveitis. In cases that are resistant to these therapies, anti-TNF agents are added. An anti-TNF-α agent, adalimumab, was recently approved for the treatment of refractory non-infectious uveitis. In this review, we provide an introduction to uveitis and summarize the effectiveness and safety of adalimumab in the treatment of non-infectious uveitis.

UR - http://www.scopus.com/inward/record.url?scp=85070317194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070317194&partnerID=8YFLogxK

U2 - 10.1080/25785826.2019.1642080

DO - 10.1080/25785826.2019.1642080

M3 - Review article

C2 - 31315546

AN - SCOPUS:85070317194

VL - 42

SP - 79

EP - 83

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 2

ER -